Yutao Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yutao Li has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Chenyang Hua
State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
1 shared publication - Chunyi Hu
Department of Biological Sciences National University of Singapore Singapore Singapore
1 shared publication Guanglei Li
College of Food Science and Engineering, Nanjing University of Finance and Economics, Nanjing, China
1 shared publication- Jianping Kong
State Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing, China
1 shared publication - Meiling Lu
Department of Biochemistry, School of Life Science and Technology, China, Pharmaceutical University , Nanjing 211198
1 shared publication - Peng Yang
China Pharmaceutical University
1 shared publication
Latest Publications
- 21 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 387 (6736) , eadr0393
Antiviral signaling of a type III CRISPR-associated deaminase
Prokaryotes have evolved diverse defense strategies against viral infection, including foreign nucleic acid degradation by CRISPR-Cas systems and DNA and RNA synthesis inhibition through nucleotide pool depletion. Here, we report an antiviral mechanism of type III CRISPR-Cas–regulated adenosine triphosphate (ATP) depletion in which ATP is converted into inosine triphosphate (ITP) by CRISPR-Cas–associated adenosine deaminase (CAAD) upon activation by either cA 4 or cA 6 , followed by hydrolysis into inosine monophosphate (IMP) by Nudix hydrolase, ultimately resulting in cell growth arrest. The cryo–electron microscopy structures of CAAD in its apo and activated forms, together with biochemical evidence, revealed how cA 4 or cA 6 binds to the CRISPR-associated Rossmann fold (CARF) domain and abrogates CAAD autoinhibition, inducing substantial conformational changes that reshape the structure of CAAD and induce its deaminase activity. Our results reveal the mechanism of a CRISPR-Cas–regulated ATP depletion antiviral strategy.
- 21 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 387 (6736) , eadr0393
Antiviral signaling of a type III CRISPR-associated deaminase
Prokaryotes have evolved diverse defense strategies against viral infection, including foreign nucleic acid degradation by CRISPR-Cas systems and DNA and RNA synthesis inhibition through nucleotide pool depletion. Here, we report an antiviral mechanism of type III CRISPR-Cas–regulated adenosine triphosphate (ATP) depletion in which ATP is converted into inosine triphosphate (ITP) by CRISPR-Cas–associated adenosine deaminase (CAAD) upon activation by either cA 4 or cA 6 , followed by hydrolysis into inosine monophosphate (IMP) by Nudix hydrolase, ultimately resulting in cell growth arrest. The cryo–electron microscopy structures of CAAD in its apo and activated forms, together with biochemical evidence, revealed how cA 4 or cA 6 binds to the CRISPR-associated Rossmann fold (CARF) domain and abrogates CAAD autoinhibition, inducing substantial conformational changes that reshape the structure of CAAD and induce its deaminase activity. Our results reveal the mechanism of a CRISPR-Cas–regulated ATP depletion antiviral strategy.